Calton & Associates’s Avanos Medical AVNS Stock Holding History

Calton & Associates’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-35	Closed	-$1K	–	405
2017 Q4	$1K	Buy	+35	New	+$1.61K	﹤0.01%	1427

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $4.34B AUM 37.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Calton & Associates's AVNS Position: Q1 2018 in Review

Calton & Associates sold out of Avanos Medical (AVNS) in Q1 2018, closing a stake of 35 shares — an estimated $1K sold.

Calton & Associates first reported a position in AVNS in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 338 funds tracked by Wall St. Rank hold AVNS as of Q1 2018.

Calton & Associates reported no remaining Avanos Medical position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 35 Avanos Medical shares in Q1 2018, an estimated $1K.
Calton & Associates first reported a position in Avanos Medical in Q4 2017 and held it in 1 quarter.
Calton & Associates's Avanos Medical position peaked at $1K in Q4 2017.
338 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.